Linagliptin noninferior for CV risk in early type 2 diabetes

Linagliptin noninferior for CV risk in early type 2 diabetes

(HealthDay)—Linagliptin is noninferior to glimepiride for adults with relatively early type 2 diabetes and elevated cardiovascular risk, according to a study published online Sept. 19 in the Journal of the American Medical Association to coincide with the annual meeting of the European Association for the Study of Diabetes, held from Sept. 16 to 20 in Barcelona, Spain.

Julio Rosenstock, M.D., from the Dallas Diabetes Research Center at Medical City, and colleagues examined cardiovascular outcomes of linagliptin versus glimepiride (sulfonylurea) in 6,042 adults with type 2 diabetes, glycated hemoglobin of 6.5 to 8.5 percent, and elevated . Patients were followed for a median of 6.3 years.

The researchers found that the primary outcome (time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 11.8 and 12.0 percent of patients in the linagliptin and glimepiride groups, respectively (hazard ratio, 0.98; 95.47 percent confidence interval, 0.84 to 1.14; P < 0.001 for noninferiority), meeting the criteria for noninferiority but not superiority (P = 0.76). Adverse events occurred in 93.4 and 94.9 percent of patients in the linagliptin and glimepiride groups, respectively, with adjudicated-confirmed acute pancreatitis in 0.5 percent of each group. Overall, 10.6 and 37.7 percent of the linagliptin and glimepiride groups had at least one hypoglycemic event (hazard ratio, 0.23; 95 percent confidence interval, 0.21 to 0.26).

"The current study demonstrates noninferior cardiovascular safety effects for linagliptin versus glimepiride when used predominantly as a second-line glucose-lowering after metformin," the authors write.

Several authors disclosed financial ties to , including Boehringer Ingelheim, which manufactures and funded the study.


Explore further

Rate of CVD mortality, MI, stroke down for patients on semaglutide

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
More Information

Copyright © 2019 HealthDay. All rights reserved.

Citation: Linagliptin noninferior for CV risk in early type 2 diabetes (2019, September 19) retrieved 19 October 2019 from https://medicalxpress.com/news/2019-09-linagliptin-noninferior-cv-early-diabetes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more